Gene therapy for RPE65-related retinal disease
- PMID: 30335549
- DOI: 10.1080/13816810.2018.1533027
Gene therapy for RPE65-related retinal disease
Abstract
Significant discoveries in the etiology and pathogenesis of inherited retinal diseases (IRDs) have been made in the last few decades. Of the large number genes that cause IRDs, bi-allelic mutations in RPE65 lead to Leber Congenital Amaurosis type 2 (LCA 2), and can also result in phenotypes described as severe early childhood onset retinal dystrophy (SECORD) and Retinitis pigmentosa 20 (RP20). Following the publication of the successful Phase-III clinical trials of gene augmentation surgery for RPE65-related IRDs with voretigene neparvovec, the FDA approved the commercial use of this pharmacologic agent in December 2017. In this perspective, ongoing and completed gene therapy trials for RPE65-related dystrophies are reviewed and challenges in patient selection, counseling and informed consent, as well as financial considerations of commercial treatment are discussed.
Keywords: Leber Congenital Amaurosis; RPE65; clinical trials; gene therapy; voretigine neparvovec.
Similar articles
-
Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.Ophthalmic Surg Lasers Imaging Retina. 2019 Oct 1;50(10):661-663. doi: 10.3928/23258160-20191009-01. Ophthalmic Surg Lasers Imaging Retina. 2019. PMID: 31671202
-
An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.Int J Mol Sci. 2021 Apr 26;22(9):4534. doi: 10.3390/ijms22094534. Int J Mol Sci. 2021. PMID: 33926102 Free PMC article. Review.
-
Available Evidence on Leber Congenital Amaurosis and Gene Therapy.Semin Ophthalmol. 2017;32(1):14-21. doi: 10.1080/08820538.2016.1228383. Epub 2016 Sep 29. Semin Ophthalmol. 2017. PMID: 27686653 Review.
-
Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network.Ophthalmic Res. 2021;64(5):740-753. doi: 10.1159/000515688. Epub 2021 Mar 8. Ophthalmic Res. 2021. PMID: 33684911
-
Gene therapy for Leber congenital amaurosis: advances and future directions.Graefes Arch Clin Exp Ophthalmol. 2012 Aug;250(8):1117-28. doi: 10.1007/s00417-012-2028-2. Epub 2012 May 29. Graefes Arch Clin Exp Ophthalmol. 2012. PMID: 22644094 Free PMC article. Review.
Cited by
-
Foveolar thickness as potential standardized structural outcome measurement in studies of Bietti crystalline dystrophy.Sci Rep. 2022 Aug 29;12(1):14706. doi: 10.1038/s41598-022-16563-y. Sci Rep. 2022. PMID: 36038562 Free PMC article.
-
An Optical Coherence Tomography-Based Measure as an Independent Estimate of Retinal Function in Retinitis Pigmentosa.Diagnostics (Basel). 2023 Nov 24;13(23):3521. doi: 10.3390/diagnostics13233521. Diagnostics (Basel). 2023. PMID: 38066762 Free PMC article.
-
Molecular diagnostic challenges for non-retinal developmental eye disorders in the United Kingdom.Am J Med Genet C Semin Med Genet. 2020 Sep;184(3):578-589. doi: 10.1002/ajmg.c.31837. Epub 2020 Aug 23. Am J Med Genet C Semin Med Genet. 2020. PMID: 32830442 Free PMC article.
-
Antioxidant and Biological Properties of Mesenchymal Cells Used for Therapy in Retinitis Pigmentosa.Antioxidants (Basel). 2020 Oct 13;9(10):983. doi: 10.3390/antiox9100983. Antioxidants (Basel). 2020. PMID: 33066211 Free PMC article. Review.
-
Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes.Mol Ther Nucleic Acids. 2024 Jun 3;35(3):102236. doi: 10.1016/j.omtn.2024.102236. eCollection 2024 Sep 10. Mol Ther Nucleic Acids. 2024. PMID: 39005878 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials
